Intellia Therapeutics, Inc. (NTLA)
$12.87-$0.24 (-1.81%) Today
Michael P. Dube - Officer
James Basta - OfficerIntellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 38,104 | $507K |
| Grant or award | 14 | 157,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
35 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John M. Leonard - Officer | Open-market sale | Common Stock | 19,890 | $12.60 | $251K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 2,785 | $13.00 | $36K | |
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 8,111 | $11.25 | $91K | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 2,641 | $16.78 | $44K | |
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 4,677 | $18.00 | $84K | |
 Frank Verwiel | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Frank Verwiel | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 Georgia Keresty | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Georgia Keresty | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
| Jesse Goodman | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Jesse Goodman | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 Brian Goff | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Brian Goff | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
| Fred E. Cohen | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Fred E. Cohen | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 William J. Chase | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| William J. Chase | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
 Muna Bhanji | Grant or award | Common Stock | 9,200 | $0.00 | - | |
| Muna Bhanji | Grant or award | Stock Option (right to buy) | 13,300 | $0.00 | - | |
| John M. Leonard - Officer | Grant or award | Common Stock | 156,400 | $0.00 | - | |
| John M. Leonard - Officer | Grant or award | Stock Option (right to buy) | 225,400 | $0.00 | - | |
| James Basta - Officer | Grant or award | Common Stock | 46,080 | $0.00 | - | |
| James Basta - Officer | Open-market sale | Common Stock | 1,211 | $13.78 | $17K | |
| James Basta - Officer | Grant or award | Stock Option (right to buy) | 65,829 | $0.00 | - | |
| David Lebwohl - Officer | Grant or award | Stock Option (right to buy) | 14,204 | $0.00 | - | |
| David Lebwohl - Officer | Grant or award | Common Stock | 9,943 | $0.00 | - | |
| Edward J. Dulac III - Officer | Grant or award | Common Stock | 61,280 | $0.00 | - | |
| Edward J. Dulac III - Officer | Grant or award | Stock Option (right to buy) | 87,543 | $0.00 | - | |
| Birgit C. Schultes - Officer | Grant or award | Common Stock | 39,200 | $0.00 | - | |
| Birgit C. Schultes - Officer | Grant or award | Stock Option (right to buy) | 56,000 | $0.00 | - | |
| Eliana Clark - Officer | Grant or award | Common Stock | 7,353 | $0.00 | - | |
| Eliana Clark - Officer | Open-market sale | Common Stock | 607 | $13.78 | $8K | |
| Eliana Clark - Officer | Grant or award | Stock Option (right to buy) | 10,505 | $0.00 | - | |
| Michael P. Dube - Officer | Grant or award | Common Stock | 17,250 | $0.00 | - | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 34,146 | $9.21 | $314K | |
| Birgit C. Schultes - Officer | Open-market sale | Common Stock | 8,508 | $9.21 | $78K | |
| James Basta - Officer | Open-market sale | Common Stock | 10,397 | $9.21 | $96K | |
| Fred E. Cohen | Open-market purchase | Common Stock | 150,000 | $9.35 | $1.40M | |
| David Lebwohl - Officer | Open-market sale | Common Stock | 11,903 | $9.21 | $110K | |
| Eliana Clark - Officer | Open-market sale | Common Stock | 9,515 | $9.21 | $88K | |
| Edward J. Dulac III - Officer | Open-market sale | Common Stock | 6,379 | $9.21 | $59K | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 2,989 | $9.21 | $28K | |
| John M. Leonard - Officer | Option exercise | Common Stock | 49,959 | $6.83 | $341K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 49,959 | $9.49 | $474K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 32,832 | $9.47 | $311K | |
| John M. Leonard - Officer | Open-market sale | Common Stock | 5,355 | $9.59 | $51K | |
| John M. Leonard - Officer | Option exercise | Common Stock | 8,557 | $6.83 | $58K | |
| John M. Leonard - Officer | Option exercise | Stock Option (right to buy) | 49,959 | $0.00 | - | |
| John M. Leonard - Officer | Option exercise | Stock Option (right to buy) | 8,557 | $0.00 | - | |
| Michael P. Dube - Officer | Open-market sale | Common Stock | 1,871 | $17.38 | $33K | |
| Birgit C. Schultes - Officer | Open-market sale | Common Stock | 31 | $17.38 | $539 | |
| William J. Chase | Open-market purchase | Common Stock | 100,000 | $10.03 | $1.00M |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| LEONARD JOHN M | Officer, Director | 22,675 | $294K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Intellia Therapeutics, Inc. (NTLA) had 11 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for NTLA runs to 35 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NTLA were filed in the last 90 days. 2 purchases are on record for this company.
5 insider sales of NTLA were filed in the last 90 days, totaling $507K.
This page tracks NTLA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NTLA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
